#### Differential early subcortical involvement in genetic frontotemporal dementia within the GENFI cohort

Bocchetta M, Todd EG, Peakman G, Cash DM, Convery RS, Russell LL, Thomas DL, Iglesias JE, van Swieten JC, Jiskoot LC, Seelaar H, Borroni B, Galimberti D, Sanchez-Valle R, Laforce Jr R, Moreno F, Synofzik M, Graff C, Masellis M, Tartaglia MC, Rowe JB, Vandenberghe R, Finger E, Tagliavini F, de Mendonça A, Santana I, Butler C,Ducharme S, Gerhard A, Danek, Levin J, Otto M, Sorbi S, Le Ber I, Pasquier F, Rohrer JD, on behalf of the Genetic Frontotemporal dementia Initiative (GENFI)

Dementia Research Centre, Department of Neurodegenerative Disease, UCL Queen Square Institute of Neurology, University College London, London, United Kingdom

## Background

Studies have previously shown evidence for cortical in presymptomatic atrophy genetic dementia frontotemporal (FTD). Whilst initial investigations have also identified early deep grey matter volume loss, little is known about the extent of subcortical involvement, particularly within subregions, and how this differs between genetic groups. We aimed to examine the specific pattern of subcortical changes (including specific subregions), to determine which areas were impaired across the different disease stages of genetic FTD.

## Methods

480 mutation carriers from the Genetic FTD Initiative (GENFI) were included (198 *GRN*, 202 *C9orf72*, 80 *MAPT*), together with 298 non-carrier cognitively normal controls (NC) (Table). Cortical and subcortical volumes of interest were generated using automated parcellation methods on volumetric 3T T1-weighted MRI scans. Mutation carriers were divided into three disease stages based on their global CDR® plus NACC FTLD score: asymptomatic (0), possibly or mildly symptomatic (0.5) and fully symptomatic (1 or more).

#### Results

In all three groups, subcortical involvement was seen at the CDR 0.5 stage prior to phenoconversion, whereas in the C9orf72 and MAPT mutation carriers there was also involvement at the CDR 0 stage (Figure). In the C9orf72 group the earliest volume changes were in thalamic subnuclei (particularly pulvinar and lateral geniculate, 9-10%) cerebellum (lobules VIIa-Crus II and VIIIb, 2-3%), hippocampus (particularly presubiculum and CA1, 2-3%), amygdala (all subregions, 2-6%) and hypothalamus (superior tuberal region, 1%). In the MAPT group changes were seen at CDR 0 in the hippocampus (subiculum, presubiculum and tail, 3-4%) and amygdala (accessory basal and superficial nuclei, 2-4%). GRN mutation carriers showed subcortical differences at CDR 0.5 in the presubiculum of the hippocampus (8%).

	NC	C9orf72			MAPT			GRN		
CDR		0	0.5	≥1	0	0.5	≥1	0	0.5	≥1
n	298	107	32	63	47	13	20	125	30	43
Age yrs	46 (13)	44 (12)	49 (12)	63 (9)	39 (11 )	47 (12)	58 (10)	46 (12)	52 (13)	64 (8)
Male %	42%	41%	38%	65%	43%	41%	65%	34%	50%	49%



Figure: Sequential pattern of neuroanatomical involvement in C9orf72, MAPT and GRN. The colour map indicates the stage defined by CDR®+NACC FTLD global scores when the specific region becomes involved, as significantly smaller than controls.

# Conclusions

C9orf72 expansion carriers show the earliest and most widespread changes including the thalamus, basal ganglia and medial temporal lobe. By investigating individual subregions, changes can also be seen at CDR 0 in *MAPT* mutation carriers within the limbic system. Our results suggest that subcortical brain volumes may be used as markers of neurodegeneration even prior to the onset of prodromal symptoms.

Acknowledgements: The Dementia Research Centre is supported by Alzheimer's Research UK, Alzheimer's Society, Brain Research UK, the Wolfson Foundation. This work was supported by the NIHR Queen Square Dementia BRU, UCLH BRC, LWENC Clinical Research Facility, UK DRI, MRC UK GENFI grant, Italian Ministry of Health, Canadian Institutes of Health Research, Bluefield Project and JPND GENFI-PROX grant. MB is supported by the Alzheimer's Society and the UK DRI. JDR is an MRC Clinician Scientist and has received funding from the NIHR Rare Diseases Translational Research Collaboration, Bluefield Project and Association for Frontotemporal Degeneration.

